Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

Early identification of multiple myeloma could help clinicians intervene more swiftly.

International Myeloma Foundation Chief Medical Office Joseph Mikhael, MD, shares how the M-Power initiative is addressing disparities through community engagement, education, and improved clinical trial access. This interview appears in the August issue of Evidence-Based Oncology.

Patients with extramedullary disease had inferior progression-free survival.

A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.